Newspaper Publication of Audited Financial Results is enclosed herewith.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Supriya Lifescience has published its audited financial results for Q4 FY26 and the full year ended March 31, 2026 in Financial Express and Loksatta newspapers. Total revenue for FY26 stood at Rs 56,750 Lakhs compared to Rs 54,734 Lakhs in FY25, representing a growth of about 3.7%. Profit after tax (PAT) increased to Rs 8,549 Lakhs from Rs 7,074 Lakhs in the previous year, marking a growth of approximately 20.8%. Annual EPS improved to Rs 153.35 per share versus Rs 126.38 in FY25. For Q4 FY26 alone, revenue from operations was Rs 44,007 Lakhs and total income was Rs 51,301 Lakhs. The company also reported basic EPS of Rs 4.21 for Q4 FY26.
The company demonstrated solid profitability growth with PAT rising over 20% year-on-year, while revenue growth was modest at under 4%. This suggests improved operational efficiency and cost management. Shareholders may view the strong earnings growth positively, though the slower revenue growth warrants monitoring of topline performance.